|
Molecular profiles of genomically high risk ER+ HER2- breast cancer tumors classified as functionally basal or luminal B by the 80-gene signature. |
|
|
Honoraria - Abbvie; Agendia; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genentech; Genomic Health; GRAIL; HERON; Immunomedics; Ipsen; Jounce Therapeutics; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Odonate Therapeutics; Pfizer; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax |
Consulting or Advisory Role - Abbvie; Agendia; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Eisai; Genentech; Genomic Health; GRAIL; HERON; Immunomedics; Ipsen; Jounce Therapeutics; Lilly; Merck; Myriad Pharmaceuticals; Novartis; Odonate Therapeutics; Pfizer; Puma Biotechnology; Roche; Samsung; Sanofi; Seagen; Syndax |
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Pfizer |
Research Funding - Seagen (Inst) |
Travel, Accommodations, Expenses - Abbvie; Agendia; Amgen; AstraZeneca; Celgene; Eisai; Genomic Health; GRAIL; Ipsen; Jounce Therapeutics; Lilly; Myriad Pharmaceuticals; Novartis; Pfizer; Puma Biotechnology; Roche; Sanofi; Seagen |
|
|
Honoraria - AstraZeneca; Celgene; Daiichi Sankyo; Eisai; Genentech; Genomic Health; Novartis; Pfizer; Puma Biotechnology; Seagen |
Consulting or Advisory Role - Amgen; AstraZeneca; Athenex; Celldex; Eisai; Puma Biotechnology |
Speakers' Bureau - Celgene; Eisai; Genentech; Genomic Health; Novartis; Pfizer; Puma Biotechnology |
|
|
|
Consulting or Advisory Role - BCI Pharma; Diiachi; Eisai; Genentech; Guardant Health; Immunomedics; Novartis; Pfizer |
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Lilly; Eisai; Genentech; Immunomedics; Merck; Novartis; Pfizer |
Research Funding - Eisai; Genentech; Merck; Novartis; Pfizer; Puma Biotechnology |
Expert Testimony - Novartis |
|
|
Consulting or Advisory Role - Agendia |
Research Funding - Agendia (Inst) |
|
|
Stock and Other Ownership Interests - Beam; Bluebird Bio; Conatus; Editas Medicine; Fate Therapeutics; Gilead Sciences; Immunogen; Immunomedics; Novocure; Pfizer; Viking Medical |
Honoraria - Agendia; AstraZeneca; Genomic Health; Lilly; Myriad Genetics; Novartis; Pfizer |
Consulting or Advisory Role - Agendia; Genentech; Genomic Health; Lilly; Myriad Genetics; Novartis; Pfizer; Puma Biotechnology |
Speakers' Bureau - Agendia; Genentech; Genomic Health; Lilly; Novartis; Pfizer; Puma Biotechnology |
Research Funding - Pfizer (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Genentech; Lilly; Novartis; Pfizer |
|
|
Employment - Baptist MD Anderson Cancer Center |
Speakers' Bureau - Agendia; Novartis |
Research Funding - Agendia (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst) |
|
|
Employment - Integra LifeSciences (I) |
Leadership - Integra LifeSciences (I) |
Stock and Other Ownership Interests - Cerebrotech Medical Systems (I); Integra LifeSciences (I); MedNeon; Targeted Medical Education, Inc. |
Honoraria - Puma Biotechnology |
Consulting or Advisory Role - Becton Dickinson; ImpediMed; Prelude Therapeutics |
Research Funding - Agendia; MedNeon; Prelude Therapeutics |
Travel, Accommodations, Expenses - Targeted Medical Education, Inc. |
|
|
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; GlaxoSmithKline; Pfizer; Puma Biotechnology; Seagen |
Speakers' Bureau - AstraZeneca; daiichsankyo; Genentech/Roche; Immunomedics |
Travel, Accommodations, Expenses - Genentech/Roche; Pfizer |
|
|
|
Speakers' Bureau - Agendia |
|
Rakhshanda Layeequr Rahman |
No Relationships to Disclose |
|
|
Employment - Texas Oncology |
Leadership - Texas Oncology |
Stock and Other Ownership Interests - Texas Oncology |
|
|
|
|
|
|
|
|
|
|
|
No Relationships to Disclose |